Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168252 | 0.94 | CCR1 (0.34) | CCR1CHRM2CCR5VNN1MAP3K7 | |
| SCHEMBL6168984 | 0.91 | CCR1 (0.33) | CCR1CHRM2CCR5VNN1 | |
| SCHEMBL6167961 | 0.91 | CCR1 (0.31) | CCR1 | |
| SCHEMBL27585058 | 0.90 | — | — | |
| SCHEMBL6167131 | 0.87 | F2RL1 (0.36) | CCR1CHRM2CCR5VNN1MAP3K7 | |
| SCHEMBL6168831 | 0.85 | CCR1 (0.30) | CCR1 | |
| SCHEMBL6168251 | 0.81 | CCR1 (0.30) | CCR1 | |
| SCHEMBL6168083 | 0.81 | F2RL1 (0.35) | CCR1CHRM2CCR5VNN1MAP3K7 | |
| SCHEMBL6167917 | 0.81 | F2RL1 (0.35) | CCR1CHRM2CCR5VNN1MAP3K7 | |
| SCHEMBL2675451 | 0.80 | CCR1 (0.42) | CCR1CHRM2CCR5VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | claimed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | claimed |
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | CCR1 32/4885CHRM2 3307/4885CCR5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.